IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.280
-0.021 (-6.82%)
At close: Mar 9, 2026, 4:00 PM EDT
0.290
+0.010 (3.57%)
After-hours: Mar 9, 2026, 6:03 PM EDT
IO Biotech Employees
IO Biotech had 80 employees as of December 31, 2024. The number of employees increased by 12 or 17.65% compared to the previous year.
Employees
80
Change (1Y)
12
Growth (1Y)
17.65%
Revenue / Employee
n/a
Profits / Employee
-$1,132,679
Market Cap
20.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80 | 12 | 17.65% |
| Dec 31, 2023 | 68 | 11 | 19.30% |
| Dec 31, 2022 | 57 | 25 | 78.13% |
| Dec 31, 2021 | 32 | 21 | 190.91% |
| Dec 31, 2020 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Daré Bioscience | 23 |
| Skye Bioscience | 16 |
| Genenta Science | 13 |
| Neuphoria Therapeutics | 8 |
| NanoViricides | 7 |
| Lexaria Bioscience | 7 |
| Intensity Therapeutics | 7 |
| Allarity Therapeutics | 7 |
IOBT News
- 5 weeks ago - IO Biotech Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - IO Biotech Announces Exploration of Strategic Alternatives - GlobeNewsWire
- 3 months ago - IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications - GlobeNewsWire
- 3 months ago - IO Biotech Announces Participation in Upcoming December Investor Conferences - GlobeNewsWire
- 4 months ago - IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 4 months ago - IO Biotech Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire
- 5 months ago - IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 - GlobeNewsWire